---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-001690"
form_type: "8-K"
ticker: "SIGY"
cik: "0001642159"
company_name: "Sigyn Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:21:21.125661+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Sigyn Therapeutics shareholder letter details expanded pipeline, S-1 financing, first-in-human study plans

## Summary
- Company reveals four therapeutic platforms: Sigyn Therapy, ImmunePrep, ChemoPrep, and ChemoPure, with pending patent for chemotherapy delivery system.
- S-1 registration statement filed with SEC to support underwritten financing; proceeds to advance programs and potentially qualify for Nasdaq listing.
- First-in-human study of Sigyn Therapy targets ESRD patients with endotoxemia; 12-15 patient IDE drafted for FDA submission.
- Clinical sites and principal investigators in place for Sigyn Therapy; treatment to be combined with dialysis.
- Pipeline expansion includes devices to enhance performance of immunotherapeutic antibodies and chemotherapy delivery.

## SEC filing metadata
- accession: 0001493152-24-001690
- form_type: 8-K
- ticker: SIGY
- cik: 0001642159
- company_name: Sigyn Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642159/000149315224001690/0001493152-24-001690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642159/000149315224001690/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-001690
- JSON: https://secwatch.observer/filing/0001493152-24-001690.json
- Plain text: https://secwatch.observer/filing/0001493152-24-001690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.